Atopic dermatitis (AD) is the most common chronic cutaneous inflammatory disease of childhood, affecting up to 25% of children; its prevalence in adulthood is currently unknown, since studies reported that AD may affect 0.3–14.3% of adult population. In the last decade, the advanced understanding of AD molecular pathways along with patient’s and physician’s demand for more effective therapies, led to the introduction of new therapeutic agents. Baricitinib is an oral JAK inhibitor highly selective for JAK1 and JAK2. Treatment with baricitinib improved the signs and symptoms of moderate-to-severe AD compared to placebo, but it will be essential to better understand the safety profile of this drug.
|Digital Object Identifier (DOI):||http://dx.doi.org/10.2147/JAA.S206387|
|Codice identificativo ISI:||WOS:000514546600001|
|Codice identificativo Scopus:||2-s2.0-85079033162|
|Titolo:||Profile of baricitinib and its potential in the treatment of moderate to severe atopic dermatitis: A short review on the emerging clinical evidence|
|Appare nelle tipologie:||1.1 Articolo in rivista|